Navigation Links
Global Growth Factors (Blood and Tissue) Market to Reach $52.1 Billion by 2012, According to New Report by Global Industry Analysts
Date:11/10/2008

Growing population, and rising percentage of aging individuals in the population mix, coupled with increasing patient demand for therapeutic efficiency, is expected to drive the world growth factors market to over $52.1 billion by the year 2012. Growth will also be encouraged by the recent success of commercialized products in new therapeutic applications such as neutropenia prevention and treatment.

San Jose, CA (PRWEB) November 10, 2008 -- Age-related conditions such as Alzheimer's disease, malignancies, trauma and autoimmune disorders necessitate the development of less-invasive and more effective therapies. Growth factors (blood and tissue) have made an indelible mark on the market as a promising and cost-effective therapeutic solution for addressing unmet medical needs. Growth factors have a wide range of opportunities, especially in treating critical conditions such as granulocytopenia, leukemia, aplastic anaemia, bone marrow transplantation, and myelodysplastic syndrome. Additionally, Human recombinant technologies have triggered these therapeutic biological products to greater heights. The steady stream of products presently in the pipeline will additional help ensure sufficient levels of product commercialization.

As stated by the recent report published by Global Industry Analysts, Inc., the United States leads the global growth factors market, in terms of discovery and product sales. Market for growth factors in the United States is expected to rise by about US$14.1 billion during the period 2008 to 2012. Europe and Japan together account for more than 32% share estimated in the year 2008. In the upcoming years, the world growth factors market is expected to make substantial progress fueled by research collaborations, government and private funding, and commercial opportunities.

In the world Blood Growth Factors market, erythropoietins represents the largest and fastest growing segment, which is expected to reach US$30.8 billion by the year 2012. Blood growth factors are slowly proving to be ideal therapeutic treatments in healthcare due to their enhanced characteristics of assuaging chronic conditions including anemia. In the untiring fight against diseases, growth factors have accomplished reasonable levels of success over the recent years. As such, development centers are busy finding new processes and formulations to enhance the benefits of blood growth factor treatments. Market for Tissue Growth Factors market is dominated by the US and Europe, together cornering over 73% share as estimated in 2008. Tissue growth factors demonstrate promising potential in areas such as wound healing, neurodegenerative diseases, and growth of musculoskeletal tissues. Successful implementation of these biological products is expected to address the unmet medical problems such as Parkinson's disease and Alzheimer's disease.

Players dominating the global and regional Growth Factors (Blood and Tissue) market include Amgen Inc, BioMimetic Therapeutics Inc, Biopharm GmbH, Bolder Biotechnology Inc, Alseres Pharmaceuticals Inc, Ceregene Inc, FibroGen Inc, FzioMed Inc, GeneMedix Plc, Insmed Inc, Johnson & Johnson, Janssen-Ortho Inc, Lonza Group, Maxygen Inc, Merck Serono International SA, NsGene A/S, PeproTech Inc, Rentschler Biotechnologie GmbH, F Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd, Genentech Inc, Shantha Biotechnics, Scil Proteins GmbH, and Wockhardt Ltd, among others.

The report titled "Growth Factors (Blood and Tissue): A Global Strategic Business Report" published by Global Industry Analysts, Inc., provides a comprehensive review of market overview, key markets worldwide, product introductions/innovations, and recent industry activity. The report analyzes market data and analytics in value sales for regions such as the United States, Japan, Europe, and Rest of World. The study also analyzes the Growth Factors (Blood and Tissue) market by the following product segments - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins) and tissue growth factors market.

For more details about this research report, please visit http://www.strategyr.com/Growth_Factors_Blood_And_Tissue_Market_Report.asp.

About Global Industry Analysts, Inc.:
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press @ StrategyR.com
Web Site http://www.StrategyR.com/

###

Read the full story at http://www.prweb.com/releases/growth_factors/blood_tissue/prweb1584284.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Corbett Selected to Host the Only Midwest Global Awards Judging Competition
2. Tata Consultancy Services to Support Roches Global Capacity Building Initiative
3. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
4. Briefing on a new Web resource to address global drinking water crisis
5. MDS Pharma Services Wins Award for Management of Global Malaria Trial
6. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
7. Resonant Medical Appoints New Vice President of Global Sales
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. The era of global aging: GSAs annual meeting to present new research on hot topics in aging
10. MEDEX Global Group & Harvard Medical International Join Forces to Create the Most Comprehensive Health Information Resource for International Travelers
11. Ultrasonix Adds Global Medical Imaging Into Its North American Sales Force
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Global Growth Factors (Blood and Tissue) Market to Reach $52.1 Billion by 2012, According to New Report by Global Industry Analysts
(Date:12/8/2016)... ... ... Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the launch of ... headquarters of Omni La Costa Resort & Spa in San Diego. , Chopra FIT ... development, a healthy lifestyle, or mental and physical healing. The week-long wellness program combines ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Center has been recognized for adherence to the highest standards of trauma, ... accreditation organizations, announced the center's president and CEO, Dr. Daniel Messina. , Among ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, ... workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical Benchmarks for ... . , According to the study, medical payments per claim in California decreased 4 ...
(Date:12/8/2016)... Charlotte, NC (PRWEB) , ... December 08, 2016 ... ... repeal Medicare and the Affordable Care Act. Dr. Botelho advocates for the mass ... A story movement gives people ongoing opportunities to share their unfortunate experiences; such ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
(Date:12/8/2016)... Dignitana, a world leader in medical scalp-cooling ... creator of the award-winning, patented Boa® system, to produce ... DigniCap® scalp cooling system. DigniCap® was cleared by the ... is the first medical scalp cooling device to receive ... features a patented tight-fitting silicone cooling cap that is ...
Breaking Medicine Technology: